Goserelin acetate
Goserelin acetate Brand names, Goserelin acetate Analogs
Goserelin acetate Brand Names Mixture
- Fluoracaine Oph Soln (Fluorescein Sodium + Proxymetacain Hcl)
- Fluorescein Sodium & Benoxinate Hydrochloride Ophtalmic Solution, Usp (Benoxinate Hydrochloride + Fluorescein Sodium)
- Fluress (Benoxinate Hydrochloride + Fluorescein Sodium)
- Fluress Liq Oph (Benoxinate Hydrochloride + Fluorescein Sodium)
Goserelin acetate Chemical_Formula
C59H84N18O14
Goserelin acetate RX_link
http://www.rxlist.com/cgi/generic/goserel.htm
Goserelin acetate fda sheet
Goserelin acetate msds (material safety sheet)
Goserelin acetate Synthesis Reference
Weber et al., U.S. Pat. 3,454,635 (1969)
Goserelin acetate Molecular Weight
1269.41 g/mol
Goserelin acetate Melting Point
No information avaliable
Goserelin acetate H2O Solubility
Soluble
Goserelin acetate State
Solid
Goserelin acetate LogP
-2.517
Goserelin acetate Dosage Forms
Supplied as a sterile and totally biodegradable d,l-lactic and glycolic acids copolymer (13.3-14.3 mg/dose) impregnated with goserelin acetate equivalent to 3.6 mg of goserelin in a disposable syringe device fitted with a 16-gauge hypodermic needle
Goserelin acetate Indication
Breast cancer; Prostate carcinoma; Endometriosis
Goserelin acetate Pharmacology
The pharmacokinetics of ZOLADEX have been determined in both male and female healthy volunteers and patients. In these studies, ZOLADEX was administered as a single 250µg (aqueous solution) dose and as a single or multiple 3.6 mg depot dose by subcutaneous route.
Goserelin acetate Absorption
Inactive orally, rapidly absorbed following subcutaneous administration
Goserelin acetate side effects and Toxicity
No experience of overdosage from clinical trials
Goserelin acetate Patient Information
BIOD00113.html
Goserelin acetate Organisms Affected
Humans and other mammals
